|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非小细胞肺癌EGFR基因少见突变及靶向治疗进展显示文摘肺癌的发病率及死亡率均位列恶性肿瘤前列,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)开启了非小细胞肺癌治疗的新纪元。EGFR基因少见突变是除经典突变外的EGFR突变,其对EGFR-TKI靶向治疗效果差异较大的问题也越来越受到关注。本文就EGFR基因少见突变的主要类别及靶向治疗等方面,对近年来的研究进展进行综述,以期为临床治疗及研究提供启示。 | 王鸯 李敏 胡成平 | 2019 | 中华医学杂志2019，99，2： | 16 |
| 2 | 第一代表皮生长因子受体酪氨酸激酶抑制剂与含铂化疗一线治疗表皮生长因子受体罕见突变阳性晚期肺腺癌患者的疗效显示文摘目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)和含铂化疗一线治疗表皮生长因子受体(EGFR)罕见突变晚期肺腺癌患者的临床疗效。方法收集2012年1月至2018年2月间,在郑州大学附属肿瘤医院经EGFR基因检测的4 276例晚期(ⅢB~Ⅳ期)肺腺癌患者的临床资料,从中筛选出99例EGFR罕见突变患者的组织样本,分析其临床病理特征,一线治疗效果、一线治疗进展后患者的治疗情况和预后。分析EGFR常见突变和罕见突变患者的预后。结果EGFR-TKIs和含铂化疗一线治疗EGFR罕见突变患者的客观缓解率分别为33.0%和27.1%,疾病控制率分别为76.5%和87.5%,差异均无统计学意义(均P>0.05);中位无进展生存时间分别为7.2和4.9个月,差异有统计学意义(P=0.009);总生存时间(OS)分别为14.3和20.7个月,差异有统计学意义(P=0.034)。多因素分析显示,远处转移和吸烟史为影响EGFR罕见突变肺腺癌患者OS的独立因素(均P<0.05)。结论对于EGFR罕见突变的晚期肺腺癌患者,一线使用第一代EGFR-TKIs与含铂化疗比较,可改善患者的近期疗效,但一线含铂化疗的患者生存时间更长。 | 李海霞 王子奇 张国伟 张米娜 郑宣轩 杨金坡 马智勇 王慧娟 | 2019 | 中华肿瘤杂志2019，41，10： | 14 |
| 3 | 非小细胞肺癌EGFR- TK非经典突变临床研究进展显示文摘目前已发现594种表皮生长因子受体(epidermal growth factor receptor,EGFR)突变类型,其中95%以上的突变存在于编码酪氨酸激酶结构域的基因的18~21外显子中。在总突变中,Del19(19号外显子缺失突变)与L858R(21号外显子点突变)突变约占84.60%,被确认为EGFR-TK敏感突变。其余突变包括:G719X(18号外显子点突变),E709X(18号外显子点突变),Del18(18号外显子缺失突变),Ins19(19号外显子插入突变),Ins20(20号外显子插入突变), L861Q(21号外显子点突变)等为非经典突变,约占总突变形式的12.10%。非小细胞肺癌(non-small cell lung cancer,NSCLC)EGFR各类型非经典突变对不同EGFR-TKIs治疗的反应差别很大,因此,了解EGFR非经典突变对靶向治疗的反应,对存在非经典突变的NSCLC患者的治疗具有重大意义。本文对NSCLC各个EGFR非经典突变的类型及针对此类突变的靶向治疗进展进行综述,以期为临床治疗提供参考。 | 赵云飞(综述) 李晓琴 刘春玲(审校) | 2019 | 肿瘤预防与治疗2019，32，6： | 12 |
| 4 | 非小细胞肺癌患者EGFR基因突变显示文摘目的了解非小细胞肺癌(NSCLC)患者的肿瘤组织表皮生长因子受体(EGFR)基因突变情况。方法利用突变扩增阻滞系统(ARMS)-聚合酶链反应(PCR)检测EGFR基因18、19、20、21外显子突变状态,并分析各突变类型与临床特征的相关性。结果共收集并匹配到资料完整的NSCLC患者673例,EGFR基因突变率为49.0%(330/673),突变类型以单一敏感型突变19del和L858R为主,占总突变的87.9%(290/330),也检测出8例(2.4%)19del、L858R混合突变及18例(5.5%)包括T790M在内的单一或混合性的耐药型突变。多因素Logistic回归分析显示,EGFR基因突变与性别、吸烟史、病理类型及癌胚抗原(CEA)水平显著相关。结论年龄低于60岁、CEA水平高的女性肺腺癌患者EGFR基因突变率高。 | 袁世洋 贺荣芝 谢军平 刘川 盛天乐 蔡婧 李里香 邹叶青 | 2019 | 中国老年学杂志2019，39，18： | 11 |
| 5 | EGFR-TKIs治疗非小细胞肺癌EGFR罕见突变的研究进展显示文摘肺癌是目前最常见的癌症,也是导致癌症死亡的首要原因。非小细胞肺癌(non-small cell lung cancer,NSCLC)占85%以上,且高达50%的亚洲NSCLC患者携带表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变。研究证明,伴有EGFR突变的NSCLC患者接受表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)治疗能获得更好的生存结果。然而,因为EGFR罕见突变相对治疗效果较差,会对研究结果带来负面影响,所以大部分研究EGFR-TKIs疗效的临床试验都不包含罕见突变患者,另外EGFR罕见突变本身就少见,就导致临床试验中这部分患者数量较少。由于EGFR罕见突变样本量少且具有高度异质性,EGFR-TKIs对EGFR罕见突变患者的疗效仍然不清楚。本文就EGFR罕见突变与EGFR-TKIs的疗效关系进行综述,为携带EGFR罕见突变的NSCLC患者合理选择治疗方式提供指导和建议。 | 杜文兴 沃杨 卢通 王元勇 矫文捷 | 2019 | 中国肺癌杂志2019，22，9： | 6 |
| 6 | Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy显示文摘Objective: Data on the clinical activity of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs) in patients with non-small-cell lung cancer(NSCLC) and uncommon EGFR mutations remain insufficient.This study aimed to investigate the effect of first-line EGFR-TKIs or platinum-based chemotherapy in NSCLC patients with uncommon EGFR mutations.Methods: We retrospectively enrolled 504 patients with EGFR-mutant NSCLC.The clinical characteristics and treatment outcomes were collected and compared between patients with common and uncommon EGFR-mutant NSCLC.Results: Seventy patients(13.9%) harboring uncommon EGFR mutations were included.Thirty of these patients received EGFR-TKIs and 40 received platinum-based chemotherapy as first-line therapy.The objective response rate(ORR) and median progression-free survival(m PFS) of patients treated with TKIs in the uncommon mutation group was significantly inferior to that in the common mutation group(ORR: 23.3% vs.51.8%,P=0.003; m PFS:7.1 vs.10.9 months,P<0.001).In the uncommon group,m PFS was similar between first-line EGFR-TKIs treatment and platinum-based chemotherapy(7.1 vs.6.1 months,P=0.893).In patients with EGFR G719 X or L861 Q mutations,the m PFS was longer in the first-line EGFR-TKIs treatment group than in the chemotherapy group,but the difference was not statistically significant(G719 X: 8.2 vs.5.8 months,P=0.061; L861 Q: 7.6 vs.4.1 months,P=0.872).Multivariate analyses identified adenocarcinoma(P=0.003) as the independent predictive factor for PFS in patients with uncommon EGFR mutations who were treated with first-line EGFR-TKIs.Conclusions: The current study demonstrated that the effect of first-line EGFR-TKIs was similar to that of platinum-based chemotherapy in patients with uncommon EGFR-mutant NSCLC.Adenocarcinoma was the independent predictive factor for PFS in uncommon EGFR-mutant NSCLC patients treated with first-line EGFRTKIs. | Jinpeng Shi Hui Yang Tao Jiang Xuefei Li Chao Zhao Limin Zhang Sha Zhao Xiaozhen Liu Yijun Jia Yan Wang Lei Xi Shijia Zhang Chunxia Su Shengxiang Ren Caicun Zhou | 2017 | Chinese Journal of Cancer Research2017，29，6： | 6 |
| 7 | First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience显示文摘Background:The antitumour efficacy of tyrosine kinase inhibitors(TKIs)in lung cancer patients with compound epidermal growth factor receptor(EGFR)mutations has not been resolved.Our study summarizes a single institutional experience of first-generation TKI therapy for lung cancers with compound EGFR mutations.Methods:A total of 106 consecutive patients with tumours bearing compound EGFR mutations were identified between January 2012 and May 2016;all patients received first-generation TKI therapy.Deletions in exon 19 and the L858R point mutation in exon 21 were considered common mutations;T790M was considered separately because of its association with TKIs resistances.Any other mutation was defined as a rare mutation.Patients were divided as follows:double common mutations(group A);common plus T790M mutations(group B);common plus rare muta-tions(group C);double rare mutations(group D);and rare plus T790M mutations(group E).A separate group of 115 consecutive patients with a single common mutation was created for comparative analysis(group F).Results:The frequency of patients with compound EGFR was 2.9%(114/3925)and their response rate to first-genera-tion TKIs was 50.9%,which was not significantly different from group F(67.0%,P=0.088).The progression-free survival(PFS)of the 106 patients receiving TKI therapy was worse than that of group F(median,9.1 vs.13.0 months,respec-tively;P<0.001).The PFS of the compound mutation group was shorter than that of the single common mutation group(median,10.1 months in group A,P=0.240;9.1 months in group B,P<0.001;9.6 months in group C,P=0.010;6.5 months in group D,P=0.048;5.4 months in group E,P=0.017).Patients with a co-occurring mutation in exon 20(excluding T790M)exhibited significantly worse PFS than the patients with other compound mutations or with a single common mutation(median,6.5 vs.9.1 vs.13.0 months,respectively,P=0.002).Conclusions:There was significant heterogeneity among the compound EGFR mutations and their response to first-generation TKIs.Individualized treatment in clinical practice should be considered for each case. | Xiangyang Yu Xuewen Zhang Zichen Zhang Yongbin Lin Yingsheng Wen Yongqiang Chen Weidong Wang Lanjun Zhang | 2018 | Cancer Communications2018，38，1： | 5 |
| 8 | Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib:a propensity score matching analysis显示文摘Objective: Although superior clinical benefits of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs) in the treatment of advanced non-small-cell lung cancer(NSCLC) had been reported,the survival difference between exon 19 deletion(Del19) and exon 21 Leu858 Arg substitution(L858 R) remains controversial.The purpose of this study is to investigate the differences in progression-free survival(PFS) and overall survival(OS) between different EGFR mutant subtypes among advanced NSCLC patients receiving gefitinib.Methods: There were 204 advanced NSCLC patients with EGFR mutations treated with gefitinib were enrolled in this retrospective cohort study.Patients were divided into the EGFR Del19 group and the L858 R mutated group according to their mutant subtype.Propensity score matching(PSM) was conducted by using a nearest-neighbor algorithm(1:1) to adjust for demographical and clinical covariates.Survival curves were constructed with the Kaplan-Meier method and compared by using the log-rank test.Results: The PFS in Del19 group was similar to that in the L858 R group [before PSM 8.6 vs.7.2 months,P=0.072; after PSM 7.3 vs.7.2 months,P=0.155].No differences were detected in OS between the L858 R and the Del19 group(before PSM 17.8 vs.13.1 months,P=0.253; after PSM 16.9 vs.13.1 months,P=0.339).The Del19 group was significantly younger compared with the L858 R mutation group in age(P=0.015).Conclusions: No significant difference was found in the PFS or OS between the Del19 and L858 R mutant NSCLC patients receiving gefitinib.The age gap might contribute to the survival differences between Del19 and L858 R groups.PSM is of important value to the elimination of potential bias. | Minglei Zhuo Qiwen Zheng Jun Zhao Meina Wu Tongtong An Yuyan Wang Jianjie Li Shuhang Wang Jia Zhong Xue Yang Hanxiao Chen Bo Jia Zhi Dong Emei Gao JingjingWang Ziping Wang | 2017 | Chinese Journal of Cancer Research2017，29，6： | 4 |
| 9 | 非小细胞肺癌少见基因突变的治疗研究进展显示文摘近年来,基因分型的深入研究使非小细胞肺癌(NSCLC)的治疗发生日新月异的变化。自2004年在NSCLC中发现表皮生长因子受体(EGFR)基因突变以来,一系列随机对照临床研究证实了酪氨酸激酶抑制剂(TKI)在EGFR基因突变型NSCLC治疗领域的主流地位。其他少见基因突变类型,如EGFR基因少见突变、KRAS基因突变、HER2基因变异、ROS1及RET基因融合、MET基因变异,BRAF基因突变及NTRK基因融合等相继被发现,使得人们越来越关注这些具有少见类型基因突变NSCLC患者的临床特点及治疗策略,也使得NSCLC的靶向治疗越来越精准。本文结合目前最新的研究成果,对NSCLC少见基因突变的治疗进展进行综述,以期为携带少见基因突变NSCLC的内科治疗提供参考与借鉴。 | 杨广建 王燕 | 2019 | 癌症进展2019，17，12： | 3 |
| 10 | NSCLC非经典EGFR突变患者临床特点及治疗预后分析显示文摘目的了解表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)对非经典突变非小细胞肺癌(non-small-cell lung cancer,NSCLC)的治疗疗效,为非经典突变患者选择最合适的靶向药物提供参考。方法收集表皮生长因子受体(epidermal growth factor receptor,EGFR)基因非经典突变的NSCLC病例,分析EGFR非经典突变患者的临床特征,对其中29例接受酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗的患者分析治疗效果。结果56例非经典突变NSCLC患者中39例单突变患者与17例双突变患者在性别、年龄、吸烟史和病理分期方面比较,差异均无统计学意义(均P>0.05)。29例接受TKI治疗的非经典突变患者客观缓解率(objective response rate,ORR)为34.5%,疾病控制率(disease control rate,DCR)为75.9%,中位无进展生存期(median progression-free survival,mPFS)为8个月。单突变与双突变患者的mPFS比较,差异无统计学意义(7个月vs 9个月,P=0.173),应用一代(n=19)与二代(n=10)TKI治疗患者的mPFS比较,差异具有统计学意义(6个月vs 9.5个月,P=0.011)。结论对接受EGFR-TKI治疗的NSCLC患者,二代TKI可能更适合于非经典突变的治疗,双突变患者疗效是否优于单突变患者,目前仍需更大的样本量提供数据支持。 | 张君 张佳梦 毕焕焕 王红梅 | 2021 | 实用肿瘤杂志2021，36，1： | 2 |
| 11 | EGFR-TKI治疗S768I突变非小细胞肺癌的研究进展显示文摘肺癌是死亡率较高的恶性肿瘤之一,近年来非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗进展迅速,尤其是表皮生长因子受体络氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)的问世,使得携带EGFR基因敏感突变患者的中位无进展生存期(median progression free survival,mPFS)达到27.7个月,但部分不常见的EGFR突变对TKI的应答效果尚不十分明确。S768I突变是EGFR20外显子携带的不常见突变之一,发生率为1%~2%。本文对不同代EGFR-TKI治疗S768I单一或复合突变的研究进行综述,旨在为临床决策提供思路。 | 段桦 崔慧娟 | 2017 | 中国肿瘤临床2017，44，22： | 2 |
| 12 | Investigation of therapeutic modalities of G719X, an uncommon mutation in the EGFR gene in non-small cell lung cancer显示文摘Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study explored the clinicopathological characteristics of the G719 X mutation and investigated the efficacy of EGFR-tyrosine kinase inhibitor(TKI) treatment and chemotherapy in patients with the G719 X mutation; the survival rate after these different treatment modalities were then analyzed in order to provide evidence for clinical treatment.Methods Clinical data of 41 patients with the G719 X mutation admitted in the Beijing Chest Hospital, Capital Medical University from September 2014 to July 2018, were collected and the EGFR mutations were detected by amplification refractory mutation system-polymerase chain reaction(ARMS-PCR). The clinicopathological characteristics of the G719 X mutation were analyzed, and the relationship among the G719 X mutation, the efficacy of different treatment modalities, and the progression-free survival(PFS) was analyzed. Results Of the 41 cases, 24(58.5%) were G719 X single mutations and 17(41.5%) were compound mutations, including G719 X/S768 I, G719 X/L861 Q, G719 X/19 del, and G719 X/c-Met compound mutation. The objective response rate(ORR) of first-line EGFR-TKI therapy was 50%(6/12), the disease control rate(DCR) was 83.3%(10/12), and the median PFS(mPFS) was 9 months. After resistance to EGFR-TKI in the previous treatment, the ORR(71.4%, 5/7) and DCR(100%, 7/7) were still high following EGFR-TKIs, by an mPFS of 8 months. The ORR of chemotherapy was 33.3%(2/6), the DCR was 100%(6/6), and the mPFS was 6 months. Conclusion G719 X is an uncommon mutation of the EGFR gene and is sensitive to many EGFR-TKIs. It can be treated with the second-or third-generation EGFR-TKIs after resistance to the first-generation EGFR-TKIs. G719 X mutation also showed favorable effect to chemotherapy. | Hua Zheng Yuan Gao Zan Liu Zhe Qian Tongmei Zhang Jie Li Hongmei Zhang Qunhui Wang Fanbin Hu Baolan Li | 2019 | Oncology and Translational Medicine2019，5，2： | 1 |
| 13 | 罕见基因突变晚期非小细胞肺腺癌靶向治疗有效1例显示文摘肺癌是我国最常见的恶性肿瘤。根据中国恶行肿瘤流行情况分析显示,肺癌发病率及死亡率居于中国恶性肿瘤之首,肺癌最常见的类型为非小细胞肺癌(non-small cell lungcancer,NSCLC),[1]。近年来分子靶向治疗在晚期NSCLC的治疗中已展示出巨大的成功。本文现就1则罕见基因突变晚期非小细胞肺腺癌靶向治疗情况进行报告。1临床资料患者,男,69岁,有吸烟史。因'咳嗽、咳痰1月余'于2018年11月13日入院。咳黄色黏痰,伴左侧胸痛、气短,无发热、心慌、心悸、夜间阵发性呼吸困难、痰中带血等不适。 | 陈思名 雷雨 白俊 | 2021 | 现代肿瘤医学2021，29，24： | 1 |
| 14 | 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究显示文摘背景与目的酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)对具有复合表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的肺癌患者的疗效尚不确切。我们对第一代TKI治疗存在复合EGFR突变肺癌患者的疗效进行了单中心研究。方法2012年1月至2016年5月共确诊106例存在复合EGFR突变的连续肿瘤患者,所有患者均接受第一代TKI治疗。外显子19缺失和外显子21的L858R点突变为常见突变;由于T790M与TKIs耐药性相关,因此单独考虑T790M;其他突变均被定义为罕见突变。患者分组如下:双重常见突变(A组),常见加T790M突变(B组),常见加罕见突变(C组),双重罕见突变(D组)和罕见加T790M突变(E组)。我们建立了一个单独的组(F组),由115例存在单一常见突变的连续患者组成,以进行比较分析。结果EGFR复合突变患者的发生率为2.9%(114/3925),对第一代TKI的反应率为50.9%,与F组相比无显著性差异(67.0%,P=0.088)。接受TKI治疗的106例患者的无进展生存期(progression-free survival,PFS)比F组短(中位数,9.1个月vs.13.0个月,P<0.001)。复合突变组的PFS短于单一常见突变组(中位数,A组10.1个月,P=0.240;B组9.1个月,P<0.001;C组9.6个月,P=0.010;D组6.5个月,P=0.048;E组5.4个月,P=0.017)。外显子20中(不包括T790M)发生共同突变的患者显示出比其他复合突变或单一常见突变患者更短的PFS,差异具有统计学意义(中位数,6.5个月vs.9.1个月vs.13.0个月,P=0.002)。结论复合EGFR突变及其对第一代TKIs的反应存在显著的异质性。在临床中对每位患者都应考虑进行个体化治疗。 | Xiangyang Yu Xuewen Zhang Zichen Zhang Yongbin Lin Yingsheng Wen Yongqiang Chen Weidong Wang Lanjun Zhang | 2019 | 癌症2019，38，10： | 1 |
| 15 | 云南省富源籍非小细胞肺癌患者表皮生长因子受体突变特征分析显示文摘目的:探讨云南省富源籍非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变率、突变特征及不同突变类型的分布特征,为该地区NSCLC的临床个体化靶向治疗提供依据。方法:选择2018年1月至2020年8月云南省富源县人民医院行EGFR检测的328例富源籍NSCLC患者,收集患者性别、年龄、民族、病理类型和EGFR检测结果等临床资料并进行统计分析。结果:NSCLC患者EGFR突变率40.55%(133/328)。女性患者EGFR突变率高于男性(P<0.01);随年龄增长,EGFR突变率呈下降趋势,≤60岁年龄组患者EGFR突变率高于>60岁年龄组(P=0.014);少数民族患者EGFR突变率与汉族相比差异无统计学意义(P=0.789);无吸烟史患者EGFR突变率高于有吸烟史患者(P<0.01);腺癌EGFR突变率高于鳞状细胞癌(P=0.002);Ⅰ~Ⅱ期患者EGFR突变率高于Ⅲ~Ⅳ期患者(P=0.013);组织标本检测突变率高于外周血检测(P=0.009)。328例患者中,EGFR单点突变率24.70%(81/328),复合突变率15.85%(52/328);常见突变率17.07%(56/328),稀有突变率23.48%(77/328)。突变率前5位的突变类型分别为L858R(10.06%)、G719X+S768I(7.32%)、19-Del(7.01%)、G719X+L861Q(6.40%)、G719X(4.21%)。133例EGFR突变患者中,稀有突变患者比例为57.89%(77/133),高于常见患者突变比例[42.11%(56/133)]。结论:富源地区女性、腺癌、无吸烟史和年轻NSCLC患者EGFR突变率较高,且稀有突变率较高。 | 荀祥翰 雷青 张祥武 郭姜艳 李磊 刘东旭 戴友德 李银 万良红 李艳丽 张娟 林艳苹 | 2021 | 肿瘤研究与临床2021，33，7： | 1 |
| 16 | 影响TKI疗效个体化差异的基因相关因素研究进展显示文摘表皮生长因子受体—酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者疗效显著,但仍存在较大的个体差异,且治疗后必然出现的耐药现象限制了该疗法进一步的临床应用。因此,科学地预测和评估TKI治疗敏感性并尽早地预防和缓解该疗法可能导致的耐药性成为临床亟待解决的问题。该文从基因层面对近年关于TKI疗效个体化差异的影响因素作一综述。 | 袁世洋 谢军平 | 2018 | 中国肿瘤2018，27，5： | 0 |
| 17 | 受体相互作用蛋白激酶4蛋白在组织中的表达NSCLC及其临床病理特征显示文摘肺癌发病率及病死率均呈升高趋势,病死率超过20%,其中非小细胞肺癌(NSCLC)在肺癌中占比最高,是肿瘤常见的死亡原因[1-3]。NSCLC细胞生长分裂较缓慢且转移扩散较晚,恶性程度低,超过半数患者在确诊时已处于中晚期,失去最佳治疗时机,5年生存率较低[4-5]。探索NSCLC发病机制并改进治疗手段、提高生存率、改善预后迫在眉睫。 | 曹路 高宝安 官莉 陈世雄 | 2021 | 中华肺部疾病杂志(电子版)2021，14，4： | 0 |
| 18 | 5例非小细胞肺癌G719X突变临床特征及治疗疗效显示文摘目的:探讨5例非小细胞肺癌G719X突变临床特征、治疗方法及疗效评估。方法:纳入2012年07月至2018年12月在空军军医大学第二附属医院呼吸与危重症医学科基因检测中心行EGFR基因检测的705例非小细胞肺癌患者,回顾性分析其G719X突变临床特征及疗效。结果:705例非小细胞肺癌患者中G719X复合突变4例,单一突变1例,G719X突变者均是Ⅳ期腺癌,无糖尿病、无高血压且未并发其它肿瘤,组织突变率低于血液、积液突变率,女性突变率高于男性,小于50岁组突变率高于大于等于50岁组,不吸烟组突变率高于吸烟组,合并骨转移、脑转移、淋巴结转移、胸膜转移组突变率分别高于无转移组,右肺肿瘤突变率略高于左肺肿瘤,但以上差异均无统计学意义;3例突变一线接受一代EGFR-TKI治疗,OS最长22月,为G719X+S768I复合突变者。结论:G719X突变以G719X+L861Q复合突变为主,Ⅳ期腺癌,无糖尿病、无高血压且未并发其它肿瘤者更易出现。在标本类型、年龄、性别、是否吸烟、病变部位、是否并发骨、脑、淋巴结、胸膜转移方面突变率比较差异均无统计学意义;一线接受一代EGFR-TKI治疗或化疗患者生存可获益。 | 房延凤 张涛 南岩东 刘伟 张海涛 马李杰 任腾 金发光 吴水淼 | 2021 | 现代肿瘤医学2021，29，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员